AstraZeneca Results Presentation Deck
Rare diseases: a new disease area in AstraZeneca
Consolidation and financial reporting to start from closing
Total revenue
Soliris
Ultomiris
Strensiq
Kanuma
Alexion pre-acquisition stand-
alone H1 and Q2 2021 revenue
Andexxa
H1 2021
$3,337m | +15%
$2,099m | +5%
$701m | +48%
$405m | +14%
$67m | +12%
$64m | n/m
Absolute values at actual exchange rates; changes at CER. Originally reported by Alexion on 20 July 2021 and not adjusted for consistency with AstraZeneca's accounting policies, not
audited and not included in AstraZeneca's H1 2021 results.
19
Q2 2021
$1,700m | +18%
$1,071m | +10%
$354m | +41%
$208m | +13%
$33m | -3%
$35m n/m
Future financial reporting
Alexion consolidated upon deal
closing on 21 July 2021
New strategic disease area
Oncology
Rare diseases
Cardiovascular, Renal &
Metabolism
Respiratory & Immunology
To be included in YTD and Q3
2021 results on 12 November
4View entire presentation